Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 381

2.

Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.

Provenzano R, Bhaduri S, Singh AK; PROMPT Study Group..

Clin Nephrol. 2005 Aug;64(2):113-23.

PMID:
16114787
3.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group..

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642
4.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators..

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46.

5.

Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking.

Jones-Burton C, Seliger SL, Brown J, Stackiewicz L, Hsu VD, Fink JC.

Nephrol Dial Transplant. 2005 Dec;20(12):2739-45.

PMID:
16188897
6.

A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.

Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.

Nephrol Dial Transplant. 2008 Oct;23(10):3240-6. doi: 10.1093/ndt/gfn255.

PMID:
18469158
7.
8.

Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.

Goh BL, Ong LM, Sivanandam S, Lim TO, Morad Z; Biogeneric EPO Study Group..

Nephrology (Carlton). 2007 Oct;12(5):431-6.

PMID:
17803464
9.

Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.

Leikis MJ, Kent AB, Becker GJ, McMahon LP.

Nephrology (Carlton). 2004 Jun;9(3):153-60.

PMID:
15189176
11.

Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.

Piccoli A, Malagoli A, Komninos G, Pastori G.

J Nephrol. 2002 Sep-Oct;15(5):565-74.

PMID:
12455725
12.

Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.

Spinowitz BS, Pratt RD; Epoetin Delta 2002 Study Group..

Curr Med Res Opin. 2006 Dec;22(12):2507-13.

PMID:
17166333
13.

Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.

Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R; Epoetin Zeta Study Group..

Curr Med Res Opin. 2008 May;24(5):1407-15. doi: 10.1185/030079908X297402 .

PMID:
18394266
14.

Once-weekly epoetin alfa for treating the anemia of chronic kidney disease.

Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC; POWER Study Group..

Clin Nephrol. 2004 Jun;61(6):392-405.

PMID:
15224803
15.

Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.

Ots PM, Pérez AR, Carrizosa CL, Ocaña CV, de Dios Sáez Garrido J, Delgado Pérez JM.

Clin Transl Oncol. 2005 Dec;7(11):486-92.

PMID:
16373059
16.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.

Hudis CA, Vogel CL, Gralow JR, Williams D; Procrit Study Group..

Clin Breast Cancer. 2005 Jun;6(2):132-42.

PMID:
16001991
17.

Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.

Rossert J, Gassmann-Mayer C, Frei D, McClellan W.

Nephrol Dial Transplant. 2007 Mar;22(3):794-800.

PMID:
17210593
18.
19.

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial.

Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, Healy H, Kerr P, Lynn K, Parnham A, Pascoe R, Voss D, Walker R, Levin A.

J Am Soc Nephrol. 2004 Jan;15(1):148-56.

Supplemental Content

Support Center